These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 15367886

  • 1. Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma.
    Niedergethmann M, Wostbrock B, Sturm JW, Willeke F, Post S, Hildenbrand R.
    Pancreas; 2004 Oct; 29(3):204-11. PubMed ID: 15367886
    [Abstract] [Full Text] [Related]

  • 2. Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection.
    Niedergethmann M, Hildenbrand R, Wolf G, Verbeke CS, Richter A, Post S.
    Int J Pancreatol; 2000 Aug; 28(1):31-9. PubMed ID: 11185708
    [Abstract] [Full Text] [Related]

  • 3. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas.
    Niedergethmann M, Hildenbrand R, Wostbrock B, Hartel M, Sturm JW, Richter A, Post S.
    Pancreas; 2002 Aug; 25(2):122-9. PubMed ID: 12142733
    [Abstract] [Full Text] [Related]

  • 4. Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer.
    Thomssen C, Schmitt M, Goretzki L, Oppelt P, Pache L, Dettmar P, Jänicke F, Graeff H.
    Clin Cancer Res; 1995 Jul; 1(7):741-6. PubMed ID: 9816040
    [Abstract] [Full Text] [Related]

  • 5. Cathepsins B and L in peripheral blood mononuclear cells of pediatric acute myeloid leukemia: potential poor prognostic markers.
    Jain M, Bakhshi S, Shukla AA, Chauhan SS.
    Ann Hematol; 2010 Dec; 89(12):1223-32. PubMed ID: 20567828
    [Abstract] [Full Text] [Related]

  • 6. Cells producing cathepsins D, B, and L in human breast carcinoma and their association with prognosis.
    Lah TT, Kalman E, Najjar D, Gorodetsky E, Brennan P, Somers R, Daskal I.
    Hum Pathol; 2000 Feb; 31(2):149-60. PubMed ID: 10685628
    [Abstract] [Full Text] [Related]

  • 7. Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo.
    Menzel K, Hausmann M, Obermeier F, Schreiter K, Dunger N, Bataille F, Falk W, Scholmerich J, Herfarth H, Rogler G.
    Clin Exp Immunol; 2006 Oct; 146(1):169-80. PubMed ID: 16968411
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Overexpression of cysteine cathepsin L is a marker of invasion and metastasis in ovarian cancer.
    Zhang W, Wang S, Wang Q, Yang Z, Pan Z, Li L.
    Oncol Rep; 2014 Mar; 31(3):1334-42. PubMed ID: 24402045
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical significance of cathepsin L and cathepsin B in dilated cardiomyopathy.
    Mehra S, Kumar M, Manchanda M, Singh R, Thakur B, Rani N, Arava S, Narang R, Arya DS, Chauhan SS.
    Mol Cell Biochem; 2017 Apr; 428(1-2):139-147. PubMed ID: 28074340
    [Abstract] [Full Text] [Related]

  • 12. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators.
    Lah TT, Cercek M, Blejec A, Kos J, Gorodetsky E, Somers R, Daskal I.
    Clin Cancer Res; 2000 Feb; 6(2):578-84. PubMed ID: 10690542
    [Abstract] [Full Text] [Related]

  • 13. Double deficiency of cathepsins B and L results in massive secretome alterations and suggests a degradative cathepsin-MMP axis.
    Tholen S, Biniossek ML, Gansz M, Ahrens TD, Schlimpert M, Kizhakkedathu JN, Reinheckel T, Schilling O.
    Cell Mol Life Sci; 2014 Mar; 71(5):899-916. PubMed ID: 23811845
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
    Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, Höfler H, Kates RE, Schmitt M.
    Clin Cancer Res; 2001 Sep; 7(9):2757-64. PubMed ID: 11555589
    [Abstract] [Full Text] [Related]

  • 16. Breast cancer cells express cathepsins B and L but not cathepsins K or H.
    Ishibashi O, Mori Y, Kurokawa T, Kumegawa M.
    Cancer Biochem Biophys; 1999 Jul; 17(1-2):69-78. PubMed ID: 10738903
    [Abstract] [Full Text] [Related]

  • 17. Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
    Harbeck N, Alt U, Berger U, Kates R, Krüger A, Thomssen C, Jänicke F, Graeff H, Schmitt M.
    Int J Biol Markers; 2000 Jul; 15(1):79-83. PubMed ID: 10763146
    [Abstract] [Full Text] [Related]

  • 18. Low expression of aldehyde dehydrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer.
    Kahlert C, Bergmann F, Beck J, Welsch T, Mogler C, Herpel E, Dutta S, Niemietz T, Koch M, Weitz J.
    BMC Cancer; 2011 Jun 27; 11():275. PubMed ID: 21708005
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD, Fu ZQ, Lin Q, Zhou Y, Zhou QB, Li ZH, Tan LP, Chen RF, Liu YM.
    World J Gastroenterol; 2015 Aug 21; 21(31):9348-57. PubMed ID: 26309360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.